Core Viewpoint - The announcement details the cash dividend distribution plan for Yabao Pharmaceutical Group Co., Ltd. for the third quarter of 2025, which was approved at the first extraordinary shareholders' meeting of 2026 on January 16, 2026 [2][4]. Dividend Distribution Details - The cash dividend per share is set at 0.2 RMB, amounting to a total cash dividend distribution of 138,400,009.20 RMB based on the total share capital of 692,000,046 shares [4]. - The distribution will be made to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the day before the equity registration [3]. Implementation Method - The dividends for unrestricted circulating shares will be distributed through the funds clearing system of China Securities Depository and Clearing Corporation Limited, with shareholders able to collect their cash dividends at their designated securities firms on the payment date [5]. - The cash dividends for the shareholder Shanshi Yabao Investment Group Co., Ltd. will be distributed directly by the company [6]. Taxation Information - For individual shareholders and securities investment funds, no income tax will be withheld at the time of cash dividend distribution. The tax will be calculated based on the holding period when the shares are sold, with specific tax rates applied depending on the duration of the holding [9]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax will be applied, resulting in a net cash dividend of 0.18 RMB per share after tax [10]. - For Hong Kong Stock Exchange investors, a similar 10% withholding tax applies, also resulting in a net cash dividend of 0.18 RMB per share [10]. - Resident corporate shareholders are responsible for their own tax payments, receiving the full cash dividend of 0.2 RMB per share [10]. Contact Information - For inquiries regarding this dividend distribution, shareholders can contact the company's Securities Legal Affairs Department at 010-57809936 [11].

截至2026年1月29日收盘，亚宝药业（600351）报收于6.77元，较前一交易日下跌0.15%，最新总市值为 46.85亿元。该股当日开盘6.71元，最高6.8元，最低6.71元，成交额达7575.24万元，换手率为1.62%。 《亚宝药业集团股份有限公司2025年三季度权益分派实施公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 近日，亚宝药业集团股份有限公司发布《2025年三季度权益分派实施公告》：每股派发现金红利0.2元 （含税），股权登记日为2026年2月5日，除权（息）日和现金红利发放日均为2026年2月6日。本次利润 分配以公司总股本692,000,046股为基数，共派发现金红利138,400,009.20元。A股股东中，无限售条件流 通股红利由中国结算上海分公司派发，部分股东由公司自行发放。对自然人股东、QFII、沪港通投资者 等不同主体按规定执行差别化个税政策。 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2026-002 亚宝药业集团股份有限公司 2025年三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.2元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2026/2/5 | － | 2026/2/6 | 2026/2/6 | 差异化分红送转： 否 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2026/2/5 | － | 2026/2/6 | 2026/2/6 | 四、 分配实施办法 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2026 年 1 月 16 日的2026年第一次临时股东会审议通过。 二、 分配方案 截至股权 ...

BEIJING ZHONGOIN LAW FIRM 北京市中勤律师事务所 中国·北京市朝阳区安苑路甲 17 号 205 室 205,No.17 Anyuan Road,Chaoyang District,Beijing 100029 ,China 电话 Tel:(86-10) 85801637, 传真 Fax:(86-10) 85801653 北京市中勤律师事务所 关于亚宝药业集团股份有限公司 2026年第一次临时股东会 律师见证法律意见书 致:亚宝药业集团股份有限公司 北京市中勤律师事务所(以下简称本所)接受亚宝药业集团股份 有限公司（以下简称公司）委托,指派律师列席公司 2026 年第一次 临时股东会,并依据《中华人民共和国公司法》(以下简称《公司法》)、 《上市公司股东会规则》(以下简称《股东会规则》)、《上海证券交易 所上市公司自律监管指引第1号一规范运作》(以下简称"自律指引") 《上海证券交易所上市公司自律监管指南第2号一业务办理》中的附 件第四号一股东会网络投票(以下简称"自律指南")等相关法律、法 规和规范性文件的规定,以及现行的《亚宝药业集团股份有限公司章 程》(以下简称《公司章程》)、《亚 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600351 证券简称：亚宝药业 公告编号：2026-001 亚宝药业集团股份有限公司 2026年第一次临时股东会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2026 年 1 月 16 日 | 1、出席会议的股东和代理人人数 | 536 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 149,144,520 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 21.5526 | | 份总数的比例（%） | | 的有关规定。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，董事长任武贤先生主持。本次会议采用现场投票和 网络投票相结合的方式召开，会议召集、召开程序符合《公司法》及《公司章程》 1 (二)股东会召开的地点：北京市经济技术开发区天华北街 11 号院 2 号楼亚宝药 业北京企管中心 11 层会议室 (三) ...

Group 1 - The core point of the article is the establishment of a new company, 亚宝药业（600351）(广东横琴)有限公司, with a registered capital of 100 million yuan, focusing on medical research, biotechnology product development, and bio-based material polymer technology research [1] - The new company is jointly held by 亚宝药业 and 亚宝药业(澳门)有限公司, indicating a strategic partnership in expanding their business operations [1] - The operational scope of the new company includes medical research and experimental development, which aligns with current trends in the biotechnology sector [1]

本报讯(记者袁传玺)天眼查App显示，近日，亚宝药业（600351）(广东横琴)有限公司成立，注册资本1 亿元，经营范围包括医学研究和试验发展、生物化工产品技术研发、生物基材料聚合技术研发等。股东 信息显示，该公司由亚宝药业、亚宝药业(澳门)有限公司共同持股。 ...

天眼查App显示，12月24日，亚宝药业（广东横琴）有限公司成立，法定代表人为任武贤，注册资本1 亿人民币，经营范围包括医学研究和试验发展、生物化工产品技术研发、生物基材料聚合技术研发等。 股东信息显示，该公司由亚宝药业、亚宝药业（澳门）有限公司共同持股。 ...

亚宝药业集团股份有限公司 2026 年第一次临时股东会会议资料 二 O 二六年一月 亚宝药业集团股份有限公司 2026 年第一次临时股东会会议资料 亚宝药业集团股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，根据《公 司法》《公司章程》《股东会议事规则》的有关规定，制订如下参会须知： 1、为保证股东会的严肃性和正常秩序，切实维护股东的合法权益，请出席 本次股东会的相关人员准时到会场签到并参加会议，参会资格未得到确认的人员， 不得进入会场。 2、股东参加股东会，依法享有发言权、表决权等各项权利，并履行法定义 务和遵守有关规定，对于扰乱股东会秩序和侵犯其他股东合法权益的，公司有权 采取必要措施予以制止并报告有关部门处理。 3、股东会召开期间，股东可以发言。股东要求发言时应先举手示意，经会 议主持人许可后，方可发言或提出问题，股东要求发言时不得打断会议报告人的 报告或其它股东的发言，不得提出与本次股东会议案无关的问题。 4、公司召开股东会按如下程序进行：首先由报告人向会议做各项议案的报 告，之后股东对各项报告进行审议讨论，股东在审议过程中提出的建议、意 ...

Core Viewpoint - The transfer of 62% equity of Taiyuan Pharmaceutical from Yabao Pharmaceutical to Shanxi Tongxiang Times Technology marks a significant shift in ownership, with the new focus on developing a technology innovation park for automotive sales and smart manufacturing instead of pharmaceutical production [1][3][9]. Group 1: Transaction Details - Yabao Pharmaceutical announced the sale of 62% of its subsidiary Taiyuan Pharmaceutical for 87.1887 million yuan, reducing its stake from 67% to 5% [1][10]. - The transaction was initiated on November 17, 2023, and completed with the registration of changes on December 19, 2023 [1][10]. - Shanxi Tongxiang has previously invested 19.8 million yuan for a 33% stake in Taiyuan Pharmaceutical, bringing its total investment to 107 million yuan for a 95% controlling interest [2][10]. Group 2: Financial Performance of Taiyuan Pharmaceutical - Taiyuan Pharmaceutical reported revenues of 906.71 million yuan in 2024, with a net loss of 1,537.85 million yuan; in the first eight months of 2025, revenues further declined to 39.04 million yuan with a net loss of 614.73 million yuan [3][11]. - The company ceased production entirely in August 2024, highlighting a stark contrast between its designed capacity and actual output [3][11]. - Yabao Pharmaceutical's overall revenue for the first three quarters of 2025 was 1.709 billion yuan, a year-on-year decrease of 19.46%, with a net profit of 215 million yuan, down 8.44% [3][11]. Group 3: New Ownership and Future Plans - Shanxi Tongxiang, established in January 2024, is primarily engaged in scientific research and technology services, with no revenue reported for 2024 and the first eight months of 2025 [4][12]. - The acquisition aims to collaborate with Shanxi Yijia Automotive Sales Service Co., a major player in the second-hand car market, to develop a technology innovation park [4][13]. - The new project, named "Intelligent Manufacturing New City," will focus on smart manufacturing, electronic information, biopharmaceuticals, new materials, and digital economy sectors, with an investment of several billion yuan [5][14]. Group 4: Strategic Adjustments by Yabao Pharmaceutical - Concurrently with the sale, Yabao Pharmaceutical completed a share buyback of 8 million shares, reducing its total shares from 700 million to 692 million, aimed at enhancing per-share earnings and shareholder value [6][15]. - The company faced setbacks in innovative drug development, notably terminating the clinical research of its diabetes drug SY-009, which had incurred a capitalized investment of 55.7933 million yuan [6][16]. - Revenue from key pediatric products, such as the Dinggui Er Qi贴, has significantly declined, with a 16.04% drop in pharmaceutical production revenue in 2024 [6][16]. Group 5: Industry Transformation Insights - This transaction reflects a broader trend in Shanxi's traditional industries, focusing on revitalizing existing assets and exploring cross-industry integration [7][17]. - The shift from a pharmaceutical production base to an automotive-focused technology park illustrates the strategic adjustments of traditional pharmaceutical companies in response to market pressures [7][17]. - The collaboration between Shanxi Tongxiang and Yijia Automotive signifies a move towards integrating traditional service industries with industrial real estate, marking a notable transformation in the region's economic landscape [7][17].